Skip to main content
GUTS logo

GUTS · Fractyl Health, Inc. · Investor Relations

Track GUTS — free
$0.97 -0.11 (-9.92%) Play latest call Q3 2026 earnings call transcript
Market Cap
$12.67M
Shares
13.26M
Volume · Nov 19 223.24K Avg daily vol (34 sessions) 804.78K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-12 Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates
2026-11-06 Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
2026-10-30 Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
2026-10-29 Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
2026-10-22 Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
2026-10-16 Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
2026-08-10 Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
2026-07-15 Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
2026-06-04 Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
2026-05-12 Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
2026-05-11 Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
2026-03-24 Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
2026-02-26 Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
2026-01-29 Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita®After GLP-1 Discontinuation
2026-01-06 Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
2026-01-05 Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
2025-12-16 Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
2025-12-02 Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
2025-11-12 Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

Past events

Date Event Type
2026-11-12 Q3 FY2026 Earnings conference call (announced in 8-K) Earnings call
2026-11-12 Fractyl Health 3Q 2026 Financial Results and Business Update Conference Conference
2026-10-16 Topline Results for Pivotal REMAIN-1 Study Conference Call Earnings call
2026-09-14 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-11 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-09-01 Fractyl Health Virtual Commercial Day: The Path to Commercializing Revita®, the Potential First Procedural Therapy for Post-GLP-1 Weight Maintenance Webcast
2026-08-12 Canaccord Genuity 46th Annual Growth Conference Conference
2026-08-10 Q2 FY2026 Earnings conference call (announced in 8-K) Earnings call
2026-07-15 REMAIN-1 Midpoint One-Year Results Conference Call Earnings call
2026-05-14 BofA Securities 2026 Health Care Conference Conference
2026-05-12 Fractyl Health 1Q 2026 Financial Results and Business Update Conference Call Earnings call
2026-03-24 Fractyl Health 4Q 2025 Financial Results and Business Update Conference Call Earnings call
2026-01-29 REMAIN-1 Midpoint Cohort 6-month Randomized Results Conference Call Earnings call
2025-12-03 8th Annual Evercore Healthcare Conference Conference
2025-11-12 Fractyl Health 3Q 2025 Financial Results and Business Update Conference Call Earnings call
2025-09-26 REMAIN-1 Midpoint Cohort 3-month Results Conference Call Earnings call
2025-08-13 Canaccord Genuity 45th Annual Growth Conference Conference
2025-08-12 Fractyl Health 2Q 2025 Financial Results and Business Update Conference Call Earnings call
2025-05-14 BofA Securities 2025 Health Care Conference Conference

Source: http://ir.fractyl.com/

Key facts CIK 1572616 CUSIP 35168W202 13F (30d) 87 filings 72 filers Visit website Investor relations